Skip to main content

Table 1 Baseline demographic and clinical characteristics in patients showing improvement in oxygenation without needing extracorporeal membrane oxygenation

From: Inhaled nitric oxide for neonates with persistent pulmonary hypertension of the newborn in the CINRGI study: time to treatment response

Variable

iNO group

n = 66

Placebo group

n = 38

P value

Birth weight, kg

 Mean (SD)

3.3 (0.55)

3.3 (0.65)

0.902

Age at enrollment, hours

 Mean (SD)

32.1 (20.63)

30.8 (18.25)

0.748

Male, n (%)

28 (42.4)

24 (63.2)

0.042

Race or ethnic group, n (%)

  

0.955

 Black

28 (42.4)

14 (36.8)

 

 Hispanic

6 (9.1)

4 (10.5)

 

 White

29 (43.9)

18 (47.4)

 

 Other

3 (4.6)

2 (5.3)

 

Primary pulmonary disease diagnosis, n (%)

 Meconium aspiration syndrome

23 (34.8)

14 (36.8)

 

 Idiopathic pulmonary hypertension

21 (31.8)

15 (39.5)

 

 Pneumonia

15 (22.7)

7 (18.4)

0.794

 Respiratory distress syndrome

5 (7.6)

1 (2.6)

 

 Lung hypoplasia syndromes

2 (3.0)

1 (2.6)

 

PaO2, mmHg

 Mean (SD)

87.8 (73.63)

66.2 (41.35)

0.058

Oxygenation index

 Mean (SD)

28.5a (15.86)

33.2 (15.5)

0.154

  1. iNO inhaled nitric oxide, PaO2 partial pressure of arterial oxygen
  2. aThe oxygenation index data are missing for 4 patients in the nitric oxide group